OGN

Organon & Co. NYSE

Healthcare ·Drug Manufacturers - General ·US · organon.com

$13.29

Mkt Cap $3.5B

52w Low $5.69 98.7% of range 52w High $13.39

50d MA $7.59 200d MA $8.41

P/E (TTM) 18.5x

EV/EBITDA 7.9x

P/B 4.6x

Debt/Equity 11.7x

ROE 24.9%

P/FCF 3.5x

RSI (14) —

ATR (14) —

Beta 0.64

50d MA $7.59

200d MA $8.41

Avg Volume 8.6M

About

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 12, 2026	BMO	0.73	0.63	-13.7%	7.69	-12.9%	-8.2%	-3.9%	-5.3%	-3.0%	-2.2%	-17.6%	—
Nov 10, 2025	BMO	0.93	1.01	+8.6%	6.78	+2.1%	+13.7%	+10.9%	+13.7%	+12.4%	+11.1%	+5.9%	—
Aug 5, 2025	BMO	0.94	1.00	+6.4%	9.67	+6.5%	-13.1%	-9.8%	-5.8%	-4.7%	-6.8%	+0.1%	—
May 1, 2025	BMO	0.89	1.02	+14.6%	12.93	-21.3%	-26.9%	-25.8%	-32.6%	-29.4%	-32.3%	-28.5%	—
Feb 13, 2025	BMO	0.92	0.90	-2.2%	14.70	+7.1%	+11.0%	+3.9%	+5.3%	+4.0%	+6.7%	+6.3%	—
Oct 31, 2024	BMO	0.90	0.87	-3.3%	17.93	+0.4%	+4.7%	+0.8%	-5.6%	-8.2%	-11.9%	-13.2%	—
Aug 6, 2024	BMO	1.06	1.12	+5.7%	20.19	-3.0%	-7.6%	-5.6%	-3.1%	-0.2%	-3.6%	+5.8%	—
May 2, 2024	BMO	0.97	1.22	+25.8%	18.83	+3.2%	+3.6%	+4.1%	+9.8%	+8.3%	+8.2%	+13.5%	—
Feb 15, 2024	BMO	0.80	0.88	+10.0%	16.36	+9.1%	+13.8%	+14.4%	+13.0%	+13.3%	+13.4%	+8.9%	—
Nov 2, 2023	BMO	1.04	0.87	-16.3%	14.65	-1.2%	-10.5%	-9.2%	-14.3%	-15.3%	-16.2%	-19.2%	—
Aug 8, 2023	BMO	0.97	1.31	+35.1%	21.80	+3.7%	+9.0%	+6.2%	+8.3%	+6.2%	+5.8%	-10.7%	—
May 4, 2023	BMO	1.18	1.08	-8.5%	24.24	-2.8%	-9.2%	-7.1%	-10.0%	-12.4%	-11.3%	-16.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 29	BNP Paribas	Downgrade	Outperform → Neutral	—	$13.32	$13.34	+0.2%	+0.2%	-0.5%	-0.2%	—	—
Apr 28	Piper Sandler	Upgrade	Underweight → Neutral	$14	$13.16	$13.19	+0.2%	+1.2%	+1.4%	+0.7%	+1.0%	—
Feb 24	Barclays	Maintains	Underweight → Underweight	—	$7.92	$7.86	-0.8%	+2.8%	-5.2%	-8.7%	-8.0%	-9.2%
Nov 11	JP Morgan	Maintains	Underweight → Underweight	—	$7.71	$7.62	-1.2%	-2.5%	+0.0%	-1.2%	-2.3%	-0.8%
Nov 11	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$7.71	$7.62	-1.2%	-2.5%	+0.0%	-1.2%	-2.3%	-0.8%
May 15	Piper Sandler	Maintains	Overweight → Overweight	—	$8.04	$8.09	+0.6%	+9.1%	+12.4%	+11.9%	+9.0%	+4.9%
May 5	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$9.59	$9.36	-2.4%	-9.1%	-4.8%	-8.7%	-5.9%	-9.2%
Apr 9	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$11.65	$11.52	-1.1%	+8.5%	-1.9%	-4.0%	-3.0%	-5.2%
Feb 14	Barclays	Maintains	Overweight → Overweight	—	$16.32	$16.14	-1.1%	-6.4%	-5.1%	-6.3%	-3.9%	-5.1%
Feb 14	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$16.32	$16.14	-1.1%	-6.4%	-5.1%	-6.3%	-3.9%	-5.1%
Sep 6	JP Morgan	Downgrade	Neutral → Underweight	—	$21.36	$20.96	-1.9%	-4.1%	-5.5%	-5.9%	-5.6%	-5.0%
May 6	Goldman Sachs	Maintains	Neutral → Neutral	—	$19.61	$19.75	+0.7%	+5.5%	+4.0%	+3.9%	+4.6%	+4.1%
May 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$19.50	$20.00	+2.6%	+0.6%	+6.1%	+4.6%	+4.5%	+5.2%
Apr 29	Piper Sandler	Maintains	Overweight → Overweight	—	$18.55	$18.69	+0.8%	+1.9%	+0.3%	+1.5%	+5.1%	+5.7%
Feb 20	Goldman Sachs	Maintains	Neutral → Neutral	—	$18.71	$18.75	+0.2%	-1.2%	-1.0%	-0.9%	-1.1%	-5.7%
Nov 22	Piper Sandler	Maintains	Overweight → Overweight	—	$11.03	$11.14	+1.0%	+1.9%	+3.0%	+3.6%	+2.4%	+3.4%
Nov 3	Goldman Sachs	Downgrade	Buy → Neutral	—	$13.11	$13.28	+1.3%	+1.4%	-4.2%	-5.3%	-6.4%	-12.9%
Oct 25	Piper Sandler	Maintains	Overweight → Overweight	—	$15.76	$15.55	-1.3%	-0.7%	-2.9%	-5.1%	-5.3%	-6.2%
Oct 11	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$17.29	$17.37	+0.5%	-0.4%	-3.8%	+0.2%	-2.5%	-4.9%
Aug 9	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$23.77	$23.88	+0.5%	-2.6%	-0.7%	-2.6%	-3.0%	-2.1%
May 8	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$22.52	$22.67	+0.7%	-3.1%	-5.7%	-4.5%	-6.1%	-7.3%
Mar 16	Raymond James	Maintains	Outperform → Outperform	—	$21.52	$21.53	+0.0%	+0.9%	+0.7%	+4.0%	+4.0%	+1.5%
Nov 4	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$25.88	$25.88	+0.0%	-5.9%	-7.3%	-9.0%	-7.8%	-4.5%
Oct 14	BofA Securities	Downgrade	Neutral → Underperform	—	$24.03	$23.22	-3.4%	-3.0%	-0.9%	+0.6%	-1.0%	-2.0%
Oct 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$23.50	$23.39	-0.5%	+0.6%	+2.3%	-0.8%	+1.3%	+2.9%
Sep 6	Piper Sandler	Upgrade	Neutral → Overweight	—	$28.50	$28.85	+1.2%	+0.7%	+1.6%	+3.0%	+4.7%	+4.2%
Aug 5	BofA Securities	Downgrade	Buy → Neutral	—	$32.41	$31.92	-1.5%	-2.8%	-2.7%	-3.1%	-2.7%	-2.2%
Jul 8	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$33.05	$32.87	-0.5%	-0.9%	-1.1%	-0.6%	-2.3%	-3.6%
Apr 27	Goldman Sachs	Maintains	Buy → Buy	—	$31.66	$31.99	+1.0%	+2.4%	+4.2%	+2.1%	+1.3%	+2.5%
Apr 6	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$35.40	$35.56	+0.5%	+2.3%	+2.3%	+1.3%	-0.6%	-1.2%
Feb 22	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$36.09	$36.10	+0.0%	-0.3%	-1.6%	-0.2%	+4.1%	+3.4%
Oct 7	Piper Sandler	Maintains	Neutral → Neutral	—	$33.07	$32.99	-0.2%	-0.7%	-1.5%	+0.4%	-0.7%	+0.2%
Sep 1	BofA Securities	Maintains	Buy → Buy	—	$33.89	$34.45	+1.7%	+2.0%	+5.1%	+5.1%	+5.2%	+3.2%
Aug 16	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$34.21	$34.24	+0.1%	+0.4%	+3.4%	-1.8%	-0.3%	-2.9%
Jul 23	Citigroup	Maintains	Buy → Buy	—	$30.92	$30.89	-0.1%	-3.6%	-4.1%	-5.8%	-3.8%	-5.5%
Jul 22	Citigroup	Maintains	Buy → Buy	—	$30.46	$30.43	-0.1%	+1.5%	-2.2%	-2.6%	-4.4%	-2.4%
Jun 15	JP Morgan	Maintains	Neutral → Neutral	—	$30.28	$30.03	-0.8%	+5.1%	+1.4%	+3.9%	-1.0%	-2.9%

Recent Filings

8-K

Organon & Co. -- 8-K Filing

Organon & Co. secured committed debt financing to fund a merger's per-share consideration and refinance existing debt, with equity awards treatment specified in the merger agreement.

Apr 27

8-K · 8.01 !! High

Organon & Co. -- 8-K 8.01: Material Event / Announcement

Organon's Audit Committee completed an independent investigation into undisclosed matters, potentially resolving governance concerns and reducing litigation risk for shareholders.

Feb 20

8-K · 7.01 ! Medium

Organon & Co. -- 8-K 7.01: Regulation FD Disclosure

Organon made its Q4 2025 earnings presentation available to investors, disclosing financial results for the quarter and full year ended December 31, 2025.

Feb 12

Data updated apr 26, 2026 5:06pm · Source: massive.com